<?xml version="1.0" encoding="UTF-8"?>
<p>Early in the course of COVID-19 infection, pro-inflammatory cytokines and chemokines are released in response to the rapid rate of virus replication leading to apoptosis [
 <xref rid="B45-pharmaceuticals-13-00096" ref-type="bibr">45</xref>]. Similar to a previous study on SARS-CoV infection, it can be speculated that viroporin 3a may activate nucleotide-binding and oligomerization domain-like(NOD-like) receptor protein 3 (NLRP3) and inflammasome, thus inducing cell pyroptosis in SARS-CoV-2 infection [
 <xref rid="B46-pharmaceuticals-13-00096" ref-type="bibr">46</xref>]. Tranilast is an antagonist of NLRP3 that inhibits the inflammasome pathway. Tranilast is a tryptophan analog used to treat allergic conditions, including bronchial asthma, atypical dermatitis, and allergic conjunctivitis [
 <xref rid="B47-pharmaceuticals-13-00096" ref-type="bibr">47</xref>]. Interestingly, the drug is registered for a Chinese clinical trial in the treatment of COVID-19 (ChiCTR2000030002).
</p>
